MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graves, L. M.
Right arrow Articles by Earp, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graves, L. M.
Right arrow Articles by Earp, H. S., III
Molecular Interventions 2:208-212 (2002)
© 2002 American Society of Pharmacology and Experimental Therapeutics

Viewpoint

Transactivation of the EGF Receptor: Is the PDGF Receptor an Unexpected Accomplice?

Lee M. Graves, Jun Han and H. Shelton Earp, III

The Department of Pharmacology, and the Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, NC 27599

SUMMARY

Saito et al. have observed that the epidermal growth factor receptor (EGFR) and the platelet-derived growth factor receptor (PDGFR) can heterodimerize at the plasma membrane and transduce signals that are measured by changes in ERK activation. Are these signaling outputs physiologically relevant? Graves, Han, and Earp discuss the observations made by Saito et al., and put forth possible mechanistic models of crosstalk between the EGFR and PDGFR. Such heterodimerization, if tightly regulated, likely has a role in normal cell physiology. There are also implications for carcinogenesis.




This article has been cited by other articles:


Home page
 BloodHome page
D. Faraone, M. S. Aguzzi, G. Ragone, K. Russo, M. C. Capogrossi, and A. Facchiano
Heterodimerization of FGF-receptor 1 and PDGF-receptor-{alpha}: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells
Blood, March 1, 2006; 107(5): 1896 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
R. E. Brown, P. L. Zhang, M. Lun, S. Zhu, P. K. Pellitteri, A. Law, G. C. Wood, and T. L. Kennedy
Morphoproteomic and Pharmacoproteomic Rationale for mTOR Effectors as Therapeutic Targets in Head and Neck Squamous Cell Carcinoma
Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 273 - 282.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. S. Gardner, B. J. Dewar, H. S. Earp, J. M. Samet, and L. M. Graves
Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation
J. Biol. Chem., November 21, 2003; 278(47): 46261 - 46269.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.